Business Wire

Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics

VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics as a new category in regenerative medicine, today ...
Business Wire

Aspect Biosystems Announces $200 Million Partnership with the Governments of Canada and British Columbia to Advance Development of Bioprinted Tissue Therapeutics

VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, today announced that it has received a $72.75 ...
Seeking Alpha

Novo Nordisk to pay $75M initially to Aspect Biosystems to develop new drugs for diabetes/obesity

Novo Nordisk (NVO) (OTCPK:NONOF) signed a licensing agreement with Canada's Aspect Biosystems to develop bioprinted tissue therapies to replace, repair or supplement biological functions inside the ...
WRIC

Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity

Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing. Aspect to ...